Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland. by Overbeck, K. et al.
Peer reviewed article
146
Original article
SWISS MED WKLY 2010 ; 140 ( 9 –10 ) : 146–152 · www.smw.ch
Impact of international consensus guidelines
on antiviral therapy of chronic hepatitis C
patients in Switzerland
Kathrin Overbeck
a
, Jean-Francois Dufour
b
, Beat Müllhaupt
c
, Beat Helbling
d
, Jan Borovicka
e
, Raffaele
Malinverni
f
, Markus Heim
g
, Darius Moradpour
h
, Andreas Cerny
i, j
, Martin Rickenbach
k
, Francesco Negro
a
,
on behalf of the Swiss Hepatitis C Cohort Study Group
a
Division of Clinical Pathology, University Hospital, Geneva, Switzerland
b
Division of Gastroenterology and Hepatology, University Hospital of Bern, Switzerland
c
Division of Gastroenterology and Hepatology, University Hospital of Zurich, Switzerland
d
Stadtspital Waid Zürich, Switzerland
e
Kantonsspital St. Gallen, Switzerland
f
Hôpital Pourtalès Neuchâtel, Switzerland
g
Division of Gastroenterology and Hepatology, University Hospital of Basel, Switzerland
h
Division of Gastroenterology and Hepatology, University Hospital of Lausanne, Switzerland
i
Division of Gastroenterology and Hepatology, University Hospital of Geneva, Switzerland
j
Clinica Moncucco Lugano, Switzerland
k
SCCS Datacenter, Lausanne, Switzerland
Summary
Aim of the study:To assess the impact of inter-
national consensus conference guidelines on the
attitude of Swiss specialists when facing the deci-
sion to treat chronic hepatitis C patients.
Methods: Questionnaires focusing on the per-
sonal situation and treatment decisions were
mailed to 165 patients who were newly diagnosed
with hepatitis C virus (HCV) infection and en-
rolled into the Swiss Hepatitis C Cohort Study
during the years 2002–2004.
Results: Survey respondents (n = 86, 52.1%)
were comparable to non-respondents with respect
to severity of liver disease, history of substance
abuse and psychiatric co-morbidities. Seventy per-
cent of survey respondents reported having been
offered antiviral treatment. Patients deferred from
treatment had less advanced liver fibrosis, were
more frequently infected with HCV genotypes 1
or 4 and presented more often with a history of
depression. There were no differences regarding
age, socio-economic background, alcohol abuse,
intravenous drug abuse or methadone treatment
when compared with patients to whom treatment
was proposed. Ninety percent of eligible patients
agreed to undergo treatment. Overall, 54.6% of
respondents and 78.3% of those considered eligi-
ble had actually received antiviral therapy by 2007.
Ninety-five percent of patients reported high sat-
isfaction with their own hepatitis C management.
Conclusions: Consistent with latest interna-
tional consensus guidelines, patients enrolled in
the Swiss Hepatitis C Cohort with a history of
substance abuse were not withheld antiviral treat-
ment. A multidisciplinary approach is warranted
to provide antiviral treatment to patients suffering
from depression.
Key words: hepatitis C virus; hepatitis C treat-
ment; barriers to treatment; treatment decision-mak-
ing; consensus guidelines
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Introduction
Chronic hepatitis C virus (HCV) infection af-
fects an estimated 170 million people worldwide
[1].Hepatitis Cmay progress to cirrhosis and liver
cancer, and is the most important indication of
liver transplantation in Europe and the USA [2].
Currently, a combination of pegylated interferon-
a (PEG-IFN-a) and ribavirin is the standard of
care (SOC) to prevent long-term sequelae of
HCV-associated liver disease [3]. However, stud-
ies in various settings and countries have sug-
gested that 62–90% of patients with confirmed
HCV infection are not receiving antiviral treat-
ment. Explanations for these low treatment rates
include provider knowledge and experience, pa-
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tient preference, medical or psychiatric co-mor-
bidities and substance abuse [4–7]. Recent feasibil-
ity studies in patients once considered too difficult
to treat, such as active injection drug users, partic-
ipants in methadone maintenance programs or
patients with psychiatric diseases, have reported
similar compliance rates and treatment outcomes
[8–12].Taking these findings into account, the US
National Institutes of Health (NIH) and French
Consensus Conference guidelines issued in the
year 2002 advocated a more inclusive approach to
treatment, urging the increase of the availability of
the best current treatment for patients who have
traditionally been considered ineligible [13, 14].
Although the conclusions of these two major con-
ferences differ regarding some details, the basic
context is similar. According to both conferences,
the general treatment indication is based on a fi-
brosis stage ≥ F2 (Metavir), whereas in genotypes
2 and 3, due to the elevated sustained virological
response rates, treatment can be started at any
time without the need to perform a liver biopsy
prior to therapy.These guidelines have influenced
the attitude of Swiss HCV experts during the past
five years, replacing the previous existing ones, is-
sued by the European Association for the Study of
the Liver Consensus Conference held in 1999
[15].
Study aims
The following issues were addressed by this
survey: (i) to evaluate the impact of the latest Con-
sensus Conference guidelines on the attitude of
Swiss HCV specialists when facing the decision to
treat patients; (ii) to evaluate patients’ personal sit-
uation at the time of diagnosis and their views on
antiviral treatment in order to identify potentially
modifiable barriers to treatment; and (iii) to assess
patients’ satisfaction concerning their hepatitis C
management.
Patients and methods
Setting
The Swiss Hepatitis C Cohort Study (SCCS) is a
multicenter study, started in September 2000 and carried
out at eight major Swiss hospitals and their local affiliated
centres. The goal of the study is to prospectively collect a
cohort of anti-HCV-positive patients to provide a frame-
work for scientific projects. A preliminary evaluation of
the baseline epidemiologic characteristics has demon-
strated that the SCCS is reasonably representative for all
anti-HCV positive individuals who have been reported
under a mandatory reporting law to the Swiss Federal Of-
fice of Public Health [16].According to the protocol, clin-
ical and laboratory data are collected on a yearly basis.
The database includes demographic data (such as age, sex,
social and educational background, occupational situa-
tion, total household income) patients’ somatic and psy-
chiatric co-morbidities, current and previous alcohol con-
sumption and substance abuse. In addition, laboratory
data, liver biopsy results and information on anti-HCV
treatments are collected. All data are recorded on stand-
ardized questionnaires by trained nurses, then independ-
ently checked for quality and consistency and entered in a
central database.The study was approved by all local eth-
ical committees and conducted according to the Helsinki
declaration. All patients consented to participate.
Patient questionnaires
Standardised anonymous questionnaires (available in
German, French and Italian) focusing on the personal sit-
uation at the time of diagnosis, initial disease management
and individual treatment decisions were mailed in January
2007 to all SCCS-enrolled persons (including drop-outs,
in order to reach patients possibly unhappy with their dis-
ease management) fulfilling the following criteria: diag-
nosis of HCV infection (positive HCV-antibodies and
positive HCV-RNA) in the years 2002/2003 and enrol-
ment in the SCCS in the years 2003/2004. This period
was chosen to assess the clinical application of the NIH
and French Consensus guidelines issued in 2002. Patients
with HCV genotypes other than 1, 2, 3 or 4 were not in-
cluded, because the consensus conferences did not issue
specific recommendations for these rare viral types. In ad-
dition, we also excluded patients with co-infection with
human immunodeficiency virus or hepatitis B virus, organ
transplantation, haemodialysis and severe cardio-pulmo-
nary diseases, because these clinical situations may imply
specific and personalised treatment strategies, and there-
fore their analysis would exceed the framework of this
study.
Physician questionnaires at site visits
For each returned patient questionnaire, responses
regarding whether anti-HCV treatment was proposed or
not by their SCCS physician were correlated with clinical
findings (HCV genotype, liver biopsy and laboratory re-
sults) existing in the SCCS database. Treatment indica-
tions were reviewed for each individual patient in order to
assess, according to Consensus guidelines, cases of poten-
tial overtreatment (= treatment in patients with fibrosis
stages F0–F1 according toMetavir or without having per-
formed a liver biopsy in genotype 1 or 4) or potential un-
dertreatment (= no treatment in patients with fibrosis
stages F2–F4 or no treatment at all and absence of a liver
biopsy). When in doubt, questionnaires were mailed to
the SCCS physician in charge of the respective patient,
asking them to state the reasons he/she considered suffi-
cient for treating or not treating the respective patient.
Moreover, site visits for a detailed chart study of the pa-
tient history were conducted if deemed necessary.
Statistical methods
In this cross-sectional analysis, different subgroups of
patients were compared: a) survey respondents vs non-re-
spondents, b) treatment proposal vs deferral, c) treatment
acceptance vs delay. Continuous variables were compared
using the two-sample Wilcoxon rank-sum (Mann-Whit-
ney) test. For categorical variables, Fisher’s exact or Pear-
son Chi
2
tests were employed whenever appropriate. p val-
ues <0.05 were considered significant. All analyses were
performed using Stata (Stata version 9, StataCorp LP,
College Station, TX, USA).
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Survey respondents vs non-respondents
Among the 165 patients fulfilling the inclu-
sion criteria, 86 (52.1%) returned their question-
naires. Regarding the subgroup of SCCS drop-out
patients (n = 20), it was found that 50% (n = 10)
sent back their completed questionnaires.
Respondents were significantly older (p =
0.007), more often employed (p = 0.044) and char-
acterized by more advanced fibrosis stages (p =
0.02) and lower viral loads (p = 0.05) when com-
pared to non-respondents (table 1). Distribution
of HCV genotypes, ALT levels, duration of dis-
ease, presence of liver biopsy, antiviral treatment,
gender, history of alcohol abuse, current or past
IVDU, current methadone treatment, current or
past medical treatment for depression or other
psychiatric disorders, and history of imprisonment
were comparable between respondents and non-
respondents.
Personal situation at the time of diagnosis
The mean age at the time of diagnosis was
43.4 years, and 54% of survey participants were
male (table 1).The majority of respondents (75%)
were living in a community (with partner, family,
friends, drug rehabilitation program) and only 1%
of them indicated not having fixed accommoda-
tion at the time of diagnosis. A total of 74% were
employed and 19% reported a yearly income
higher than 80000 CHF. One fifth (21%) were
non-Swiss nationals. Furthermore, 23% indicated
that their mother tongue was different from the
language in which the medical consultations were
held, and 41% of the latter reported communica-
tion difficulties (mediocre to absent knowledge of
the language in which the medical consultation
was held). Diagnosis of HCV infection was estab-
lished mainly in an outpatient setting, in 48% of
cases by general practitioners, 7% by gastroenter-
ologists or hepatologists, and 13% by other spe-
cialists. In 26% of cases, the diagnosis was made at
the time of a hospitalization (in 12% due to medi-
cal/surgical reasons, 14% for drug/alcohol abuse
management) and in another 7% on occasion of a
blood donation. Around two thirds of survey
respondents (72%) claimed to have heard of HCV
before being diagnosed. Moreover, 55% of pa-
tients reported knowing at least one other person
affected by chronic hepatitis C. In contrast, 28%
of patients reported that they did not know that
HCV existed at all before learning about their di-
agnosis.
Patients considered eligible for treatment
by HCV specialists
Sixty-one patients (71%) reported that antivi-
ral treatment was recommended by their HCV
specialist (table 2). Patients who were deferred
from treatment were more frequently known for a
history of depression (p = 0.022), had less advanced
fibrosis stages (p <0.05), and were more frequently
characterized by genotypes 1 or 4 (p = 0.001).
There were no differences in the number of
performed liver biopsies or fibrosis stages when
patients with genotypes 1 or 4 were compared
with patients presenting genotypes 2 or 3 (data not
shown). There were no differences regarding age,
gender, socio-economic background, ALT level,
viral load, presence of cirrhosis, current/past alco-
hol consumption or intravenous drug use, current
methadone treatment, or psychiatric disorders
other than depression, when comparing patients
considered eligible for treatment with those to
whom antiviral therapy was not proposed.
Evaluation of treatment indications
By matching patient responses to the question
regarding whether antiviral treatment was pro-
posed by their HCV specialist with clinical data
from the SCCS database, we were able to evaluate
indications and possible contraindications for an-
Results
Table 1
Comparison between survey respondents vs non-respondents.
Survey respondents
(n = 86)
Survey
non-respondents
(n = 79) p test
n (%), or mean ± SD n (%), or mean ± SD
Male gender 46 (53.5) 47 (59.5) 0.43 B
Age (y) 43.3 ± 1.34 38.5 ± 1.09 0.007 C
Swiss nationality 68 (79.1) 55 (69.6) 0.16 B
Higher education 23 (26.7) 12 (15.2) 0.07 B
Unemployed 22 (24.7) 32 (40.5) 0.044 B
Yearly income >80000 CHF 17 (20) 8 (10.1) 0.084 B
Self-reported full working ability 51 (59.3) 40 (50.6) 0.263 B
Self-reported full social ability 58 (67.4) 42 (53.2) 0.061 B
Mean duration of disease (y) 16.8 ± 1.22 (n = 73) 15.2 ± 1.61 (n = 67) 0.33 C
HCV genotype 1/2/3/4 39 (45.3) / 6 (7) /
36 (40.7) / 6 (7)
45 (57.7) / 3 (3.9) /
25 (32) / 5 (6.4)
0.43 A
Liver biopsy 50 (58.1) 38 (48.1) 0.32 B
Mean fibrosis stage 2.3 ± 0.21 1.7 ± 0.17 0.02 C
Cirrhosis 10 (11.6) 3 (3.9) 0.08 A
ALT (x ULN) 2.12 ± 0.22 2.89 ± 0.42 0.39 C
HCV RNA (IU/ml) 871,570 ± 206,998 1,686,395 ± 605,670 0.05 C
Ever received antiviral therapy 38 (44.2) 25 (31.7) 0.09 B
Past alcohol drinking >20 g/d 45 (47.1) 38 (48.1) 0.53 B
Past IVDU 48 (61.21) 53 (67.9) 0.138 B
History of depression 23 (26.7) 19 (24.1) 0.69 B
History of psychiatric disorders 12 (13.9) 9 (11.4) 0.62 B
History of imprisonment 15 (17.4) 14 (17.7) 0.96 B
Current alcohol drinking ≥20 g/d 12 (14.0) 8 (10.1) 0.84 B
Current IVDU 4 (5.1) 7 (8.9) 0.09 A
Current methadone treatment 7 (8.9) 8 (10.1) 0.21 B
A Fisher’s exact test
B Pearson chi
2
CTwo-sampleWilcoxon rank-sum (Mann-Whitney)
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tiviral therapy. Treatment decisions in conformity
with guidelines were observed in 64 cases (74%).
There were only five cases of suspected overtreat-
ment (= treatment in the absence of significant
liver fibrosis (stages F0–F1 according to Metavir)
[n = 2] or without having performed a liver biopsy
in genotype 1 or 4 infection [n = 3]) and 17 cases
of potential undertreatment (= no treatment in
patients with significant fibrosis (stages F2–F4
according to Metavir)) [n = 2] or no treatment and
absence of a liver biopsy [n = 15]) were observed.
As described above, additional information was
assessed either by questionnaires directed at the
respective HCV specialist, or, in more complex
cases, by a review of the patient chart during site
visits. The main reasons stated in favour of a po-
tential overtreatment were (multiple answers were
allowed): highly motivated patients who insisted
on treatment (3 cases out of 5), extrahepatic mani-
festations (2 cases) and the desire to eradicate
HCV before a pregnancy (2 cases). Concerning
the potential undertreatment, physicians stated the
following reasons for deferral: normal liver en-
zymes (6 cases out of 17), missed follow-up visits
(2 cases), current psychiatric disorder (2 cases),
past psychiatric disorder (1 case), ongoing IVDU
(1 case), ongoing alcohol abuse (1 case), chaotic
lifestyle of patient (1 case) and low viral load
(1 case).
Treatment acceptance by patients
Of the 61 patients considered eligible for
treatment, 45 patients (74%) agreed to start treat-
ment immediately, 12 (20%) considered to start
treatment at a later date, and 4 (7%) refused treat-
ment altogether (table 3). In other words, 93% of
the patients to whom antiviral therapy was offered
showed a generally favourable attitude towards
treatment.
When compared to those who considered an-
tiviral therapy at a later date, patients who were
ready to begin treatment immediately were signif-
icantly older (p = 0.0008), more often employed (p
= 0.033), were more frequently diagnosed in an
outpatient setting (p = 0.043), had a longer dura-
tion of disease (p = 0.004) and presented less fre-
quently with a history of alcohol abuse (p = 0.04),
a history of depression (p = 0.05) or current psy-
chiatric disorders other than depression (p =
0.009). Patients who wished to postpone therapy
declared the following reasons for doing so (mul-
tiple answers were possible): unstable personal sit-
uations (6 cases out of 12), fear of losing jobs
(3 cases), pregnancy plans (3 cases), wish to finish
studies (1 case), current alcohol abuse (1 case), cur-
rent depressive episode (1 case), and a plan to go
on holiday (1 case).The four patients who refused
treatment altogether did not share any distinct
common demographic or disease-related features.
They indicated the following reasons for their de-
cision (multiple answers were accepted): doubts in
the efficacy of treatment (4 cases out of 4), fear of
side effects (3 cases), fear of reimbursement prob-
lems/costs (2 cases), other intensive medical treat-
ment already in progress (1 case), and old age (1
case).
Gender, the current living and family situa-
tion, level of education, nationality or language
difficulties did not seem to influence survey par-
ticipants when it came to the decision to accept or
defer treatment. Furthermore, the fact of knowing
another person with HCV and having shared ex-
periences regarding antiviral treatment did not
seem to affect personal treatment decisions either.
Prescription rates
Treatment prescription rates were then evalu-
ated and it was found that by July 2007, 47 patients
Table 2
Comparison of patients according to treatment allocation.
Treatment
proposed
(n = 61)
No treatment
proposed
(n = 25)
p test
n (%) or mean ± SD n (%) or mean ± SD
Male gender 38 (62.3) 8 (32.0) 0.110 B
Mean age 43.75 ± 1.48 41.11 ± 0.92 0.389 C
Swiss nationality 48 (78.7) 20 (80.0) 0.799 A
Higher education 14 (22.9) 9 (36.0) 0.214 B
Employed 44 (72.1) 20 (80.0) 0.469 A
Income >80000 CHF 13 (21.3) 4 (16.0) 0.574 A
Living alone 17 (27.9) 4 (16.0) 0.331 A
Children 20 (32.8) 12 (48.0) 0.185 B
Working ability 100% 35 (57.4) 16 (64.0) 0.57 B
Social ability 100% 41 (67.2) 17 (68.0) 0.944 B
Language difference 15 (24.6) 5 (20.0) 0.782 A
Diagnosis as outpatient 41 (67.2) 17 (68.0) 0.752 B
Diagnosis at hospitalization 16 (26.2) 6 (24.0) B
Mean duration of disease (y)
(n = 54)
17.15 ± 1.36 15.62 ± 2.73 0,602 C
Genotype 1–4 24 (39.3) 21 (84.0) 0,001 A
Genotype 2–3 37 (60.7) 4 (16.0)
Liver biopsy 41 (67.2) 7 (28.0) 0.001 B
Fibrosis stage 2.75 ± 0.23 1.25 ± 0.25 0.05 C
Cirrhosis 8 (13.1) 2 (8.0) 0,717 A
ALT, times the ULN 2.08 ± 0.18 2.25 ± 0.58 0,165 C
HCV RNA, IU/ml 721,652 ± 191,679 1,260,412 ± 525,164 0.426 C
History of alcohol >20 g/d 35 (56.4) 10 (40.0) 0,123 B
History of IVDU 36 (59.0) 12 (48.0) 0,350 B
History of depression 14 (22.9) 12 (48.0) 0.022 A
History of other psychiatric
disorders
9 (14.8) 3 (12.0) 1,000 A
History of imprisonment 13 (21.3) 2 (8.0) 0.212 A
Current alcohol ≥20 g/d 10/37 (27.0) 2/10 (20.0) 0.703 B
Current IVDU 4/37 (10.8) 0 (0) 0,560 A
Current methadone treatment 6/37 (16.2) 1/10 (10.0) 0,662 A
Current depression 5/37 (13.5) 3/10 (30.0) 0.394 A
Current other psychiatric
disorder
3/37 (8.1) 2/10 (20.0) 0.587 A
A Fisher’s exact test; B Pearson chi
2
; C Two-sampleWilcoxon rank-sum (Mann-Whitney)
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(55% of respondents and 77% of those considered
eligible) had actually received antiviral therapy.
Of the 45 patients originally ready to start therapy
immediately, two had to refrain from treatment
because of the diagnosis of concomitant severe
diseases (lymphoma, oropharyngeal cancer). Re-
garding the 12 patients planning to postpone ther-
apy, eight had not started treatment yet, mainly
because of missed follow-up visits, ongoing IVDU
and/or alcohol abuse or planned pregnancy. Con-
cerning the four patients who had initially refused
therapy, none of them reconsidered their own de-
cisions.
Patient satisfaction
Patients reported high rates of accordance
with their disease management: 93% of patients
who were considered eligible for antiviral treat-
ment indicated that they felt well informed when
they made their decision for or against treatment.
In the group of patients to whom treatment was
not recommended, 95% found that the reasons for
treatment deferral were well explained and an-
other 95% agreed with their physicians’ decision
not to treat.
Figure 1 shows a flow-chart schematising a
comprehensive overview of antiviral treatment el-
igibility, treatment readiness and prescription
rates of survey participants.
Table 3
Univariate analysis: Comparison of treatment readiness.
Willing to start
treatment immediately
(n = 45)
Willing to postpone
treatment
(n = 12)
p test
n (%) or mean ± SD n (%) or mean ± SD
Male gender 28 (62.2) 8 (66.7) 0.700 A
Mean age 45.64 ± 1.43 33.17 ± 2.58 0.0008 C
Swiss nationality 35 (77.8) 10 (93.3) 0.675 A
Higher education 10 (22.2) 2 (16.7) 0.675 A
Employed 36 (80.0) 7 (58.3) 0.033 A
Income >80000 CHF 10 (22.2) 2 (16.7) 0.675 A
Living alone 14 (31.1) 2 (16.7) 0.139 A
Children 18 (40.0) 2 (16.7) 0.182 A
Self reported full working
ability
27 (60.0) 7 (58.3) 0.917 B
Self reported full social ability 31 (68.9) 8 (66.7) 0.883 B
Language difference 11 (24.4) 3 (25.0) 1.000 A
Diagnosis as outpatient 33 (73.3) 3 (25.0) 0.043 A
Diagnosis during
hospitalization
9 (20.0) 6 (50.0)
Mean duration of disease (y)
(n = 50)
19.6 ± 1.50 9.55 ± 2.70 0,004 C
Genotype 1–4 16 (35.6) 6 (50.0) 0.346 A
Genotype 2–3 29 (64.4) 6 (50.0)
Liver biopsy 32 (71.1) 5 (41.7) 0.088 A
Mean fibrosis stage 2.7 ± 0.22 2 ± 0 0.520 C
Cirrhosis 7 (15.6) 0 0.325 A
ALT, times the ULN 2.07 ± 0.22 1.89 ± 0.33 C
Mean HCV-RNA (IU/ml) 549,540 ± 190,743 1,248,707 ± 643,350 0.504 C
History of alcohol drinking
>20 g/d
20 (44.4) 10 (83.3) 0.04 B
History of IVDU 26 (57.8) 9 (75.0) 0.335 A
History of depression 8 (17.8) 6 (50.0) 0.05 A
History of other psychiatric
disorders
6 (13.3) 2 (16.7) 0.670 A
History of imprisonment 8 (17.8) 4 (33.3) 0.254 A
Current alcohol drinking
>20 g/d
7/26 (26.9) 2/8 (25.0) 1 A
Current IVDU 2/26 (7.6) 2/8 (25.0) 0.229 A
Current methadone
treatment
3/26 (11.5) 3/8 (37.5) 0.126 A
Current depression 2/26 (7.6) 3/8 (37.5) 0.072 A
Current other psychiatric
disorder
0 (0) 3/8 (37.5) 0.009 A
Knew about HCV before
being diagnosed
31 (68.9) 9 (75.0) 1 A
Knows other persons with
HCV
21 (46.7) 9 (75.0 ) 0.089 A
A: Fisher’s exact test; B: Pearson chi
2
; C: Two-sampleWilcoxon rank-sum (Mann-Whitney)
All survey participants
n = 86
Eligible for treatment
n = 61 (70.1%)
Treatment
accepted
n = 45
Treatment received
n = 47 (54.7%)
Treatment
postponed
n = 12
Treatment
refused
n = 4
Not eligible for treatment
n = 25 (29.9%)
n = 4
n = 43
Figure 1
Flow-Chart illustrating antiviral treatment eligibility
and prescription rates of survey participants with chronic
hepatitis C infection.
Discussion
In this retrospective multicenter study, it was
found that 71% of 86 anti-HCV positive patients
were considered eligible for antiviral treatment,
and that 77% of these actually received treatment
by 2007.The results are comparable with those of
several large international randomized trials of
PEG-IFN-a and ribavirin combination therapy
stating treatment eligibility rates between 66–
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78% [17–19]. In contrast, when analyzing the re-
sults of studies conducted in smaller centres in dif-
ferent countries and settings, often regarding spe-
cial patient subgroups, treatment eligibility and
prescription rates are dramatically lower, ranging
between 10 and 30% [6, 7–22].
Our study shows a fair acceptance of Consen-
sus guidelines by Swiss HCV specialists regarding
antiviral treatment.This finding is in line with re-
sults of a recent survey among Swiss internists re-
flecting a generally favourable attitude towards in-
ternational guidelines [23]. In fact, patients with a
history of alcohol or intravenous drug use, current
methadone treatment, psychiatric disorders other
than depression as well as cirrhotic patients were
not excluded from antiviral treatment. Patients
considered ineligible treatment candidates were
characterized by less advanced fibrosis stages
when compared to patients judged eligible. Fur-
thermore, patients to whom antiviral treatment
was not proposed presented with the so-called dif-
ficult to treat genotypes 1 or 4 significantly more
often. The SOC still represents the most effective
means of preventing long-term sequelae from
chronic HCV infection [3]. Thus, physicians
should be encouraged to offer SOC also to pa-
tients infected by the more challenging genotypes
1 and 4, in order to make viral clearance more
achievable. Moreover, patients considered ineligi-
ble presented a history of depression more fre-
quently.As shown in various feasibility studies [24,
25], successful antiviral treatment is possible in
this subgroup of patients as long as a multidiscipli-
nary psychological support is provided. However,
in this study it was found that patients suffering
from psychiatric diseases other than depression
were, in accordance with Consensus guidelines,
not excluded from antiviral treatment.
Nevertheless,25.6%of treatmentdecisionshad to
be re-evaluated in regard to their conformity to Con-
sensus guidelines,hereby showing a clear tendency to-
wards possible undertreatment. Among the reasons
stated by physicians for deferring from treatment, the
presence of normal liver enzymes was one of themost
frequent answers. As numerous studies published in
recent years demonstrated a poor correlation between
the level of transaminases and the grade of liver fibro-
sis [26, 27],HCV experts today relymuch less on liver
enzyme values when facing the decision for or against
antiviral treatment, compared to during the survey pe-
riod (2002–2004).Regarding patients’ views on antivi-
ral treatment, we found that readiness for immediate
treatment was associated with older age and a longer
duration of disease. Interestingly, those patients were
more frequently diagnosed at an outpatient setting,
hereby indicating less severemedical or psychiatric co-
morbidities that could possibly interfere with antiviral
treatment. Patients without a history of alcohol abuse
or psychiatric disorders obviously feel more ready to
face possible treatment side effects.The main reasons
for treatment delay indicated by patients were an un-
stable personal situation and the fear of losing their job
because of treatment–related reduced performance.
Ten percent of eligible patients refused antivi-
ral treatment altogether, which is in line with find-
ings from other studies [28, 29].The leading rea-
son for patient refusal was their doubts regarding
the efficacy of treatment. Unfortunately, as there
is currently no alternative to the SOC, which of-
fers rates of viral eradication between 50 and 80%
[3, 30], those concerns are understandable. Pa-
tients with minimal liver disease can be advised to
wait for the arrival of newmolecules, which are ex-
pected to be on the market in two or three years
from now.The most promising candidates include
direct inhibitors of the HCV nonstructural (NS) 3
protease, and both nucleoside and non-nucleoside
inhibitors of the NS 5B RNA-dependent RNA
polymerase.These agents represent the concept of
specifically targeted antiviral therapy for HCV
(STAT-C) – a new strategy in which the main goal
is to increase the effectiveness of antiviral re-
sponses across all genotypes, with shorter treat-
ment duration and better tolerability [31, 32].
Interestingly, the current living and family sit-
uation, level of education, nationality or language
difficulties did not seem to influence survey par-
ticipants regarding the decision to accept or defer
treatment. Furthermore, the fact of knowing an-
other person with HCV and having shared experi-
ences regarding antiviral treatment did not seem
to affect personal treatment decisions either.
Besides the well-known limitations due to a
relatively small study population and the retro-
spective design, we acknowledge that our study re-
flects the disease management of chronic hepati-
tis C in a highly specialized setting, and that the
treatment of patients by general practitioners or in
small medical centres might differ. Concerning a
possible selection bias of patients eventually char-
acterized by an above-average compliance due to
their participation in the SCCS and their partici-
pation in this survey, we would like to mention
that patient questionnaires were sent to all pa-
tients fulfilling the above-cited inclusion criteria,
including all drop-out patients of the SCCS in or-
der to reach also patients possibly discontent with
their disease management or otherwise character-
ized by a problematic follow-up. 50% of patients
that originally dropped out of the SCCS neverthe-
less sent back their completed questionnaires, thus
showing a response rate comparable to patients
still participating in the cohort study.
In conclusion, we found that international
Consensus guidelines on hepatitis C disease man-
agement are accepted and applied by Swiss HCV
experts, offering antiviral treatment to a large pro-
portion of patients, including those previously
considered difficult to treat. Nevertheless, further
multidisciplinary efforts are needed to extend the
access to antiviral treatment for patients infected
by genotype 1 or 4 and patients suffering from de-
pression. Patients showed a generally very favora-
ble attitude towards antiviral treatment.
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